Barclays upgrades Dr Reddy's to overweight

Barclays upgrades Dr. Reddy's Laboratories Ltd to "overweight" from "equalweight" while maintaining its target at 2,801 rupees, saying recent share falls are overdone.

Dr. Reddy's shares are down 8.6 percent so far for the year, as part of a shift to domestic cyclicals from exporters and defensive sectors, compared to a 15.6 percent gain in the Nifty.

Barclays says Dr. Reddy's is now trading at a discount to historical valuations and its peers, while it remains "positive" on the drug-maker's fundamentals.

Dr. Reddy's shares were up nearly 1 percent as of 10:18 a.m.

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

EDITORIAL OF THE DAY

  • India must follow China on its path to the future

    There are many theories, real and imagined, doing the rounds in the national and international media about Barack Obama’s overtures to ‘rebalance

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

Chander Mohan Sethi

CMD, Reckitt Benckiser India

COLUMNIST

Arun Nigavekar

Will the adventurous UGC succeed?

The impact of the Modi government on the education sector ...

Zehra Naqvi

The urge to tell stories

One wants to tell a story, like Scheherzade, in order ...

Dharmendra Khandal

Don’t interfere with nature

Just before we celebrated the news of tiger numbers swelling, ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture